CEO, Ablynx and board member of
European Biopharmaceutical Enterprises
After completing his post-doctoral research in Germany, Edwin began a commercial career with successful periods spent at Amersham International, Enzymatix and Raggio-Italgene. From 1993-2001, first as CEO and later as Chairman, he was responsible for the growth of Oxford Asymmetry (OAI) through a series of venture rounds cumulating in a flotation (LSE) in 1998 at a value of £120 million. This was followed by a sale of the company to Evotec Biosystems in 2000 for £316 million. During this period, OAI grew from four people to over 250. Over the past eight years, Edwin has played an important role at Board level (primarily as Chairman) in over 15 European life science companies. During this time he has been involved in a number of financing rounds, a series of M&A transactions and four IPOs and one SPO.
Edwin has been Chairman of Ablynx since 2004, and in 2006 he accepted the offer by Ablynx's Board of Directors to extend his role as Chairman to include that of Chief Executive Officer. Apart from and in addition to his duties as CEO and Chairman of the Company, Edwin Moses is the Chairman of Lectus Therapeutics Ltd. (UK), a member of the Board of Directors of the European Biopharmaceutical Enterprises and it is anticipated that he will become the Chairman of the Board of Capricorn Health-tech Fund (Belgium).